Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Celltrion Successful in French National and Regional Tenders to Supply Infliximab, Trastuzumab and Bevacizumab Biosimilars

Jun 20, 2024

On 20 June 2024, Korea Biomedical Review reported that Celltrion has successfully applied to be the exclusive supplier of Remsima® (biosimilar to Janssen’s Remicade® (infliximab)), Herzuma® (biosimilar to Roche’s Herceptin® (trastuzumab)) and Vegzelma® (biosimilar to Genentech’s Avastin (bevacizumab)) to France’s largest pharmaceutical procurement Group (Union des Hopitaux pour les Achats (UniHA)) The supply arrangement will continue until June 2027. 

Celltrion has also secured a 4 year-contract to supply Herzuma and Vegzelma to the Bretagne regional public hospital network in France.  

This follows Celltrion’s recent tender successes regarding Remsima® and Herzuma® in Peru (May 2024) and Remsima SC® in Denmark (April 2024), Norway (February 2024) and Sicily (January 2024).  In February 2024, Celltrion also secured a series of tenders in Peru to supply Herzuma® (trastuzumab biosimilar), Truxima® (rituximab biosimilar) and Yuflyma® (adalimumab biosimilar).